Recent studies point to an association between the late-onset sporadic Parkinson’s disease (PD) and single nucleotide polymorphisms (SNPs) rs1559085 and rs27852 in Ca2+-dependent protease calpain inhibitor calpastatin (CAST) gene. This finding is of interest since loss of CAST activity could result in over activated calpain, potentially leading to Ca2+ dysregulation and loss of substantia nigra neurons in PD. We explored the association between CAST SNPs and late-onset sporadic PD in the Han Chinese population. The study included 615 evaluable patients (363 male, 252 female) with PD and 636 neurologically healthy controls (380 male, 256 female) matched for age, gender, ethnicity, and area of residence. PD cases were identified from the PD cohort of the Chinese National Consortium on Neurodegenerative Diseases (www.chinapd.cn). A total of 24 tag-SNPs were genotyped capturing 95% of the genetic variation across the CAST gene. There was no association found between any of the polymorphisms and PD in all models tested (co-dominant, dominant-effect and recessive-effect). Similarly, none of the common haplotypes was associated with a risk for PD. Our data do not support a significant association between the CAST gene polymorphisms and late onset sporadic PD in the Han Chinese population.
References
[1]
Parkinson J (2002) An Essay on the Shaking Palsy. J Neuropsych Clin Neurosci 14: 223–236.
[2]
Zhang ZX, Roman GC, Hong Z, Wu CB, Qu QM, et al. (2005) Parkinson’s disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet 365: 595–597.
[3]
Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, et al. (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68: 384–386.
[4]
Paleacu D, Schechtman E, Inzelberg R (2005) Association between family history of dementia and hallucinations in Parkinson disease. Neurology 64: 1712–1715.
[5]
Ward CD, Hess WA, Calne DB (1983) Olfactory impairment in Parkinson’s disease. Neurology 33: 943–946.
[6]
Jellinger KA (2012) Neuropathology of sporadic Parkinson’s disease: evaluation and changes of concepts. Mov Disord. 27: 8–30.
[7]
Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, et al. (2010) Global PD Gene Expression (GPEX) Consortium. PGC-1α, a potential therapeutic target for early intervention in Parkinson’s disease. Sci Transl Med 2: 52ra73.
[8]
Lesage S, Brice A (2009) Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 18(R1): R48–59.
[9]
Maraganore DM, de Andrade M, Lesnick TG, Strain KJ, Farrer MJ, et al. (2005) High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet 77: 685–693.
[10]
Fung HC, Scholz S, Matarin M, Simón-Sánchez J, Hernandez D, et al. (2006) Genome-wide genotyping in Parkinson’s disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol 5: 911–916.
[11]
Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, et al. (2009) Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet 124: 593–605.
[12]
Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, et al. (2010) Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 74: 97–109.
[13]
Allen AS, Satten GA (2009) A novel haplotype-sharing approach for genome-wide case-control association studies implicates the calpastatin gene in Parkinson’s disease. Genet Epidemiol 33: 657–667.
[14]
Allen AS, Satten GA (2010) SNPs in CAST are associated with Parkinson disease: a confirmation study. Am J Med Genet B Neuropsychiatr Genet 153: 973–979.
[15]
Perier C, Vila M (2012) Mitochondrial biology and Parkinson’s disease. Cold Spring Harb Perspect Med 2: a009332.
[16]
Wronski R, Tompa P, Hutter-Paier B, Crailsheim K, Friedrich P, et al. (2000) Inhibitory effect of a brain derived peptide preparation on the Ca++-dependent protease, calpain J Neural Transm. 107: 145–157.
[17]
Mouatt-Prigent A, Karlsson JO, Agid Y, Hirsch EC (1996) Increased M-calpain expression in the mesencephalon of patients with Parkinson’s disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? Neuroscience 73: 979–987.
[18]
LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, et al. (2011) AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 10: 309–319.
[19]
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinic-pathological study of 100 cases, J Neurol Neurosurg Psychiatry. 55: 181–184.
[20]
International HapMap Consortium (2003) The International HapMap Project. Nature 426: 789–796.
[21]
Buetow KH, Edmonson M, MacDonald R, Clifford R, Yip P, et al. (2001) High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Natl Acad Sci USA 98: 581–584.
[22]
Lewontin RC (1988) On measures of gametic disequilibrium. Genetics. 120: 849–852.
[23]
Stephens M, Donnelly P (2003) A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73: 1162–1169.
[24]
Purcell S, Cherny SS, Sham PC (2003) Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics. 19: 149–150.
[25]
Saad M, Lesage S, Saint-Pierre A, Corvol JC, Zelenika D, et al. (2011) Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson’s disease in the European population. Hum Mol Genet 20: 615–627.
[26]
Liu X, Cheng R, Verbitsky M, Kisselev S, Browne A, et al. (2011) Genome-wide association study identifies candidate genes for Parkinson’s disease in an Ashkenazi Jewish population. BMC Med Genet 12: 104–120.
[27]
Kumar KR, Weissbach A, Heldmann M, Kasten M, Tunc S, et al. (2012) Frequency of the D620N mutation in VPS35 in Parkinson disease. Arch Neurol 69: 1360–1364.
[28]
Lesage S, Condroyer C, Klebe S, Lohmann E (2012) French Parkinson’s Disease Genetics Study Group, et al (2012) EIF4G1 in familial Parkinson’s disease: pathogenic mutations or rare benign variants? Neurobiol Aging 33: 2233.e1–2233.e5.
[29]
Camins A, Verdaguer E, Folch J, Pallàs M (2006) Involvement of calpain activation in neurodegenerative processes. CNS Drug Rev 12: 135–148.
[30]
Wendt A, Thompson VF, Goll DE (2004) Interaction of calpastatin with calpain: a review. Biol Chem 385: 465–472.
[31]
Crocker SJ, Smith PD, Jackson-Lewis V, Lamba WR, Hayley SP, et al. (2003) Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson’s disease. J Neurosci 23: 4081–4091.
[32]
Kupershmidt I, Su QJ, Grewal A, Sundaresh S, Halperin I, et al. (2010) Ontology-based meta-analysis of global collections of high-throughput public data. PLoS ONE 5: e13066.
[33]
Simunovic F, Yi M, Wang Y, Macey L, Brown LT, et al. (2009) Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson’s disease pathology. Brain 132: 1795–1809.
[34]
Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, et al. (2002) The structure of haplotype blocks in the human genome. Science 296: 2225–2229.
